GAK
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
T Sites Probabilities
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O14976 | S26 | Sugiyama | GAK DNAJC26 | sALDFLAGPGsLGGAsGRDQsDFVGQTVELGELRLRVRRVL |
| O14976 | S399 | Sugiyama | GAK DNAJC26 | RGGTERLFTNLKDTSSKVIQsVANyAKGDLDISyITSRIAV |
| O14976 | T223 | Sugiyama | GAK DNAJC26 | DYSWSAQRRALVEEEITRNTtPMYRtPEIIDLYSNFPIGEK |
| O14976 | T228 | Sugiyama | GAK DNAJC26 | AQRRALVEEEITRNTtPMYRtPEIIDLYSNFPIGEKQDIWA |
| O60664 | T170 | Sugiyama | PLIN3 M6PRBP1 TIP47 | AVDATRGAVQSGVDKTKsVVtGGVQsVMGsRLGQMVLsGVD |
| P04040 | T29 | Sugiyama | CAT | SDQMQHWKEQRAAQKADVLttGAGNPVGDKLNVItVGPRGP |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P07437 | T55 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | tyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEPGtMDs |
| P08238 | T487 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVRKRG |
| P08865 | T94 | Sugiyama | RPSA LAMBR LAMR1 | VsVIssRNtGQRAVLKFAAAtGAtPIAGRFtPGTFTNQIQA |
| P09923 | S111 | Sugiyama | ALPI | DRFPYLALSKTYNVDRQVPDsAATATAYLCGVKANFQTIGL |
| P0DPH7 | T56 | Sugiyama | TUBA3C TUBA2 | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVVD |
| P13639 | T5 | Sugiyama | EEF2 EF2 | ________________MVNFtVDQIRAIMDKKANIRNMsVI |
| P14314 | T469 | Sugiyama | PRKCSH G19P1 | WGsWIGPDHDKFSAMKyEQGtGCWQGPNRstTVRLLCGKEt |
| P14618 | T45 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | TFLEHMCRLDIDsPPItARNtGIICtIGPAsRsVEtLKEMI |
| P23284 | T81 | Sugiyama | PPIB CYPB | IFGLFGKTVPKTVDNFVALAtGEKGFGYKNSKFHRVIKDFM |
| P29692 | S162 | Sugiyama | EEF1D EF1D | AKKPAtPAEDDEDDDIDLFGsDNEEEDKEAAQLREERLRQY |
| P29692 | T147 | Sugiyama | EEF1D EF1D | PQtQHVsPMRQVEPPAKKPAtPAEDDEDDDIDLFGsDNEEE |
| P30050 | T18 | Sugiyama | RPL12 | ___MPPKFDPNEIKVVYLRCtGGEVGAtsALAPKIGPLGLs |
| P37802 | T190 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | GKNVIGLQMGtNRGAsQAGMtGyGMPRQIL___________ |
| P46776 | T95 | Sugiyama | RPL27A | LDKLWtLVsEQtRVNAAKNKtGAAPIIDVVRsGyyKVLGKG |
| P49368 | T430 | Sugiyama | CCT3 CCTG TRIC5 | GGGASEMAVAHALTEKSKAMtGVEQWPyRAVAQALEVIPRT |
| P50990 | T286 | Sugiyama | CCT8 C21orf112 CCTQ KIAA0002 | MNFsKGEENLMDAQVKAIADtGANVVVtGGKVADMALHYAN |
| P50990 | T293 | Sugiyama | CCT8 C21orf112 CCTQ KIAA0002 | ENLMDAQVKAIADtGANVVVtGGKVADMALHYANKYNIMLV |
| P62826 | T21 | Sugiyama | RAN ARA24 OK/SW-cl.81 | MAAQGEPQVQFKLVLVGDGGtGKttFVKRHLtGEFEKKyVA |
| P68363 | T56 | Sugiyama | TUBA1B | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVID |
| P68363 | T82 | Sugiyama | TUBA1B | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| Q00610 | T606 | SIGNOR|PSP | CLTC CLH17 CLTCL2 KIAA0034 | EMNLMHAPQVADAILGNQMFtHYDRAHIAQLCEKAGLLQRA |
| Q58FF8 | T263 | Sugiyama | HSP90AB2P HSP90BB | FSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVWKRD |
| Q6PEY2 | T56 | Sugiyama | TUBA3E | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVVD |
| Q71U36 | T56 | Sugiyama | TUBA1A TUBA3 | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVID |
| Q71U36 | T82 | Sugiyama | TUBA1A TUBA3 | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q9BQE3 | T56 | Sugiyama | TUBA1C TUBA6 | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVID |
| Q9BQE3 | T82 | Sugiyama | TUBA1C TUBA6 | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| Q9H3D4 | T281 | EPSD|PSP | TP63 KET P63 P73H P73L TP73L | PSHLIRVEGNSHAQYVEDPItGRQSVLVPyEPPQVGTEFTT |
| Q9H3D4 | T46 | EPSD|PSP | TP63 KET P63 P73H P73L TP73L | PAHFSWKESYYRSTMSQsTQtNEFLsPEVFQHIWDFLEQPI |
| Q9H3Z4 | S10 | Sugiyama | DNAJC5 CLN4 | ___________MADQRQRsLstsGEsLyHVLGLDKNATSDD |
| Q9H7D7 | S121 | Sugiyama | WDR26 CDW2 MIP2 PRO0852 | ASSSLATPELGSSLKKKKRLsQsDEDVIRLIGQHLNGLGLN |
| Q9UI15 | T190 | Sugiyama | TAGLN3 NP25 | GQNVIGLQMGSNKGAsQAGMtGyGMPRQIM___________ |
| Q9Y266 | T145 | Sugiyama | NUDC | AENHEAQLKNGsLDsPGKQDtEEDEEEDEKDKGKLKPNLGN |
| Q9Y295 | T62 | Sugiyama | DRG1 NEDD3 | LITPKGGGGGGPGEGFDVAKtGDARIGFVGFPSVGKSTLLS |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.000002 | 5.705 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.000016 | 4.796 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.000019 | 4.711 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.000009 | 5.040 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.000011 | 4.961 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.000012 | 4.905 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.000016 | 4.808 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.000040 | 4.393 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.000046 | 4.341 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.000047 | 4.325 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.000061 | 4.214 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.000074 | 4.133 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.000074 | 4.133 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.000067 | 4.176 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.000067 | 4.176 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.000105 | 3.977 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.000123 | 3.911 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.000125 | 3.902 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.000126 | 3.901 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.000137 | 3.864 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.000147 | 3.831 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.000148 | 3.830 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.000174 | 3.760 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.000185 | 3.734 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.000200 | 3.699 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.000195 | 3.710 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.000245 | 3.611 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.000277 | 3.558 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.000275 | 3.561 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.000318 | 3.498 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.000356 | 3.449 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.000366 | 3.436 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.000392 | 3.406 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.000420 | 3.377 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.000480 | 3.319 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.000533 | 3.273 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.000564 | 3.249 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.000620 | 3.208 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.000702 | 3.154 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.000702 | 3.154 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.000704 | 3.152 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.000743 | 3.129 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.000795 | 3.100 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.000863 | 3.064 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.000895 | 3.048 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.001026 | 2.989 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.001005 | 2.998 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.001006 | 2.997 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.001034 | 2.986 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 0.001091 | 2.962 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.001281 | 2.892 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.001342 | 2.872 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 0.001338 | 2.874 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 0.001370 | 2.863 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.001507 | 2.822 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 0.001623 | 2.790 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.001665 | 2.779 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.001711 | 2.767 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.001819 | 2.740 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.001822 | 2.740 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.001879 | 2.726 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.002017 | 2.695 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.001934 | 2.713 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.002062 | 2.686 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.002469 | 2.607 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.002469 | 2.607 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.002469 | 2.607 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 0.002469 | 2.607 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.002469 | 2.607 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.002469 | 2.607 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 0.002204 | 2.657 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.002296 | 2.639 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 0.002322 | 2.634 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.002541 | 2.595 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.002541 | 2.595 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.002182 | 2.661 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.002327 | 2.633 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.002232 | 2.651 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.002558 | 2.592 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.002593 | 2.586 | 1 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.002721 | 2.565 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.002854 | 2.544 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.002890 | 2.539 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.002890 | 2.539 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.002890 | 2.539 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.003152 | 2.501 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.003167 | 2.499 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.003167 | 2.499 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.003168 | 2.499 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.003204 | 2.494 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.003204 | 2.494 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.003369 | 2.473 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.003369 | 2.473 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.003678 | 2.434 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.003835 | 2.416 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.003835 | 2.416 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.004009 | 2.397 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.004362 | 2.360 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.004362 | 2.360 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.004536 | 2.343 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.004443 | 2.352 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.004573 | 2.340 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.004656 | 2.332 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.004870 | 2.312 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.004870 | 2.312 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 0.004998 | 2.301 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.004998 | 2.301 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.005244 | 2.280 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.005248 | 2.280 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 0.005426 | 2.266 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 0.005426 | 2.266 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 0.005426 | 2.266 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.005822 | 2.235 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.005738 | 2.241 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.006269 | 2.203 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.006112 | 2.214 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.006499 | 2.187 | 1 | 1 |
| Adherens junctions interactions | R-HSA-418990 | 0.006734 | 2.172 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.006877 | 2.163 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.007010 | 2.154 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.007457 | 2.127 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.009420 | 2.026 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.009420 | 2.026 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.009420 | 2.026 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.009420 | 2.026 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.009731 | 2.012 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.007922 | 2.101 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.009316 | 2.031 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.009316 | 2.031 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.009316 | 2.031 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.009731 | 2.012 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.009372 | 2.028 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.009372 | 2.028 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.007695 | 2.114 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.009349 | 2.029 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.007879 | 2.104 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.007765 | 2.110 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.008460 | 2.073 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.008584 | 2.066 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.009316 | 2.031 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.009353 | 2.029 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.008913 | 2.050 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.007879 | 2.104 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 0.010148 | 1.994 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.010487 | 1.979 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.010768 | 1.968 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.010782 | 1.967 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.010882 | 1.963 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.011250 | 1.949 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.011653 | 1.934 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 0.011653 | 1.934 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.011815 | 1.928 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.012169 | 1.915 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.012234 | 1.912 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.012254 | 1.912 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 0.014376 | 1.842 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.014662 | 1.834 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.014662 | 1.834 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.014662 | 1.834 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.014662 | 1.834 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.012938 | 1.888 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.013991 | 1.854 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.014315 | 1.844 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.012928 | 1.888 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.013536 | 1.869 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.014315 | 1.844 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.014783 | 1.830 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.015618 | 1.806 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.015618 | 1.806 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.015720 | 1.804 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.017249 | 1.763 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.017249 | 1.763 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 0.017357 | 1.761 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.017568 | 1.755 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.017568 | 1.755 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.017568 | 1.755 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.017568 | 1.755 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.017870 | 1.748 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.018351 | 1.736 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.019077 | 1.719 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.019247 | 1.716 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.019406 | 1.712 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 0.020219 | 1.694 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 0.020219 | 1.694 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 0.020219 | 1.694 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.020772 | 1.683 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.020772 | 1.683 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.020772 | 1.683 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.020772 | 1.683 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.020772 | 1.683 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.024274 | 1.615 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 0.021723 | 1.663 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.022676 | 1.644 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.024478 | 1.611 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.021394 | 1.670 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.023083 | 1.637 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.024478 | 1.611 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.023249 | 1.634 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.022229 | 1.653 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.024754 | 1.606 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.025976 | 1.585 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.026845 | 1.571 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.026845 | 1.571 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.026883 | 1.571 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 0.026883 | 1.571 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.026883 | 1.571 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 0.026883 | 1.571 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.026883 | 1.571 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 0.026883 | 1.571 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 0.026883 | 1.571 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.027095 | 1.567 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.029159 | 1.535 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.029159 | 1.535 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.030623 | 1.514 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.031262 | 1.505 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.032011 | 1.495 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.032173 | 1.493 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 0.032173 | 1.493 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.032173 | 1.493 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.032595 | 1.487 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.032630 | 1.486 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.033557 | 1.474 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.033687 | 1.473 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 0.034300 | 1.465 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 0.034300 | 1.465 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.034300 | 1.465 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 0.035378 | 1.451 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.035378 | 1.451 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 0.042411 | 1.373 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 0.041249 | 1.385 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.039089 | 1.408 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.043277 | 1.364 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.044530 | 1.351 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.044279 | 1.354 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.041249 | 1.385 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.044530 | 1.351 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.038878 | 1.410 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.042411 | 1.373 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 0.042411 | 1.373 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.043180 | 1.365 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.039477 | 1.404 | 1 | 0 |
| Gastrulation | R-HSA-9758941 | 0.042381 | 1.373 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.042411 | 1.373 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.036164 | 1.442 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.038102 | 1.419 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.042353 | 1.373 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.046219 | 1.335 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.046300 | 1.334 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.046732 | 1.330 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.047531 | 1.323 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.047685 | 1.322 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.048573 | 1.314 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.049073 | 1.309 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.050048 | 1.301 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.050258 | 1.299 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 0.050649 | 1.295 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 0.051156 | 1.291 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.051156 | 1.291 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.051156 | 1.291 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 0.051156 | 1.291 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 0.051156 | 1.291 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.051470 | 1.288 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.051700 | 1.287 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.054038 | 1.267 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.056996 | 1.244 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.057237 | 1.242 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.059372 | 1.226 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.060481 | 1.218 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.062791 | 1.202 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.062791 | 1.202 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 0.080666 | 1.093 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.080666 | 1.093 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 0.080666 | 1.093 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 0.080666 | 1.093 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 0.080666 | 1.093 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.075157 | 1.124 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.075157 | 1.124 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.067996 | 1.168 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.072805 | 1.138 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.080666 | 1.093 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.080666 | 1.093 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.076469 | 1.117 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.080666 | 1.093 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.064293 | 1.192 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.070042 | 1.155 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.076469 | 1.117 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.071814 | 1.144 | 1 | 1 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.081713 | 1.088 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.065566 | 1.183 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.080666 | 1.093 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.067015 | 1.174 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.067588 | 1.170 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.071658 | 1.145 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.076797 | 1.115 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.070749 | 1.150 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.068665 | 1.163 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.064818 | 1.188 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.075157 | 1.124 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.070334 | 1.153 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.083959 | 1.076 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.075157 | 1.124 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.081438 | 1.089 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.080666 | 1.093 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.063405 | 1.198 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.071658 | 1.145 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.075808 | 1.120 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.075183 | 1.124 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.086562 | 1.063 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.086562 | 1.063 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.088233 | 1.054 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.088233 | 1.054 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.088933 | 1.051 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.088960 | 1.051 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.091431 | 1.039 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 0.091431 | 1.039 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 0.091431 | 1.039 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.091839 | 1.037 | 0 | 0 |
| Translation | R-HSA-72766 | 0.095306 | 1.021 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.095527 | 1.020 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.095527 | 1.020 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.095527 | 1.020 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.097265 | 1.012 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.097265 | 1.012 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.098827 | 1.005 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.099604 | 1.002 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.101410 | 0.994 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.102373 | 0.990 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 0.102430 | 0.990 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 0.102430 | 0.990 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 0.102430 | 0.990 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 0.102430 | 0.990 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 0.102430 | 0.990 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 0.102430 | 0.990 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 0.102430 | 0.990 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.102586 | 0.989 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.102586 | 0.989 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 0.102586 | 0.989 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 0.102586 | 0.989 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.102768 | 0.988 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.102768 | 0.988 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.102768 | 0.988 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.105546 | 0.977 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 0.108554 | 0.964 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.108554 | 0.964 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 0.134191 | 0.872 | 0 | 0 |
| Defective SLC12A1 causes Bartter syndrome 1 (BS1) | R-HSA-5619104 | 0.134191 | 0.872 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 0.134191 | 0.872 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 0.134191 | 0.872 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 0.134191 | 0.872 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 0.164829 | 0.783 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.164829 | 0.783 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.164829 | 0.783 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 0.194385 | 0.711 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.194385 | 0.711 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.194385 | 0.711 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 0.194385 | 0.711 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.222897 | 0.652 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 0.222897 | 0.652 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 0.222897 | 0.652 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.114089 | 0.943 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.114089 | 0.943 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 0.250401 | 0.601 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 0.250401 | 0.601 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 0.250401 | 0.601 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 0.250401 | 0.601 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 0.250401 | 0.601 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 0.250401 | 0.601 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.125903 | 0.900 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 0.137990 | 0.860 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 0.137990 | 0.860 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.276933 | 0.558 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 0.276933 | 0.558 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 0.276933 | 0.558 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 0.276933 | 0.558 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 0.150317 | 0.823 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.302528 | 0.519 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.302528 | 0.519 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 0.302528 | 0.519 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 0.302528 | 0.519 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 0.302528 | 0.519 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.302528 | 0.519 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.302528 | 0.519 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.302528 | 0.519 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.175565 | 0.756 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 0.175565 | 0.756 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.188427 | 0.725 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.188427 | 0.725 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 0.327219 | 0.485 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.327219 | 0.485 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 0.327219 | 0.485 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 0.327219 | 0.485 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.327219 | 0.485 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.133739 | 0.874 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.141936 | 0.848 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.227655 | 0.643 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.176257 | 0.754 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.267374 | 0.573 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.267374 | 0.573 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.158983 | 0.799 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.172747 | 0.763 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.147751 | 0.830 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.320226 | 0.495 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.259900 | 0.585 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.269539 | 0.569 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.146108 | 0.835 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.308410 | 0.511 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.270208 | 0.568 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.192273 | 0.716 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.227655 | 0.643 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.192273 | 0.716 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.320226 | 0.495 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.165595 | 0.781 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.164776 | 0.783 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.118187 | 0.927 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.308410 | 0.511 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.308410 | 0.511 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.191903 | 0.717 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.141936 | 0.848 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.259900 | 0.585 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.231382 | 0.636 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.246164 | 0.609 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.175565 | 0.756 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.201413 | 0.696 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.227655 | 0.643 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.172484 | 0.763 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.308410 | 0.511 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 0.222897 | 0.652 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.150317 | 0.823 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.150296 | 0.823 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.281548 | 0.550 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.318171 | 0.497 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.231299 | 0.636 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.199984 | 0.699 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 0.222897 | 0.652 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 0.222897 | 0.652 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 0.125903 | 0.900 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 0.162852 | 0.788 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.201413 | 0.696 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.185172 | 0.732 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.212574 | 0.672 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.307071 | 0.513 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.146108 | 0.835 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.296816 | 0.528 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.118517 | 0.926 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.150317 | 0.823 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.162852 | 0.788 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 0.302528 | 0.519 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.110219 | 0.958 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.298659 | 0.525 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.307071 | 0.513 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 0.298659 | 0.525 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.175565 | 0.756 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.141936 | 0.848 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.114410 | 0.942 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 0.240868 | 0.618 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.141936 | 0.848 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.214496 | 0.669 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.120401 | 0.919 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.214496 | 0.669 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.117871 | 0.929 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.170619 | 0.768 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.169203 | 0.772 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.160807 | 0.794 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 0.134191 | 0.872 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 0.134191 | 0.872 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 0.134191 | 0.872 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 0.164829 | 0.783 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.164829 | 0.783 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 0.222897 | 0.652 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.250401 | 0.601 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 0.250401 | 0.601 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 0.175565 | 0.756 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.125714 | 0.901 | 0 | 0 |
| PKA activation | R-HSA-163615 | 0.201413 | 0.696 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 0.201413 | 0.696 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.150296 | 0.823 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.126524 | 0.898 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.165814 | 0.780 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.293868 | 0.532 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.240772 | 0.618 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.240772 | 0.618 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.320226 | 0.495 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.223787 | 0.650 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.239040 | 0.622 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.308410 | 0.511 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.254525 | 0.594 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.153340 | 0.814 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.139152 | 0.857 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.321495 | 0.493 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.171753 | 0.765 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.327219 | 0.485 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.227655 | 0.643 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.164776 | 0.783 | 1 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.202849 | 0.693 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 0.327219 | 0.485 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 0.222897 | 0.652 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 0.150317 | 0.823 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.302528 | 0.519 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.117871 | 0.929 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.298659 | 0.525 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.113522 | 0.945 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.229122 | 0.640 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.191903 | 0.717 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.294027 | 0.532 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.213590 | 0.670 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.253626 | 0.596 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.152749 | 0.816 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 0.164829 | 0.783 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 0.194385 | 0.711 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 0.222897 | 0.652 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 0.250401 | 0.601 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 0.250401 | 0.601 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 0.276933 | 0.558 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.150317 | 0.823 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.188427 | 0.725 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.327219 | 0.485 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.125714 | 0.901 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.158809 | 0.799 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.167466 | 0.776 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 0.176257 | 0.754 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.194203 | 0.712 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.194203 | 0.712 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.221897 | 0.654 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.259900 | 0.585 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.146108 | 0.835 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.318171 | 0.497 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.278112 | 0.556 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.246164 | 0.609 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.211852 | 0.674 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.127063 | 0.896 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.184540 | 0.734 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.147386 | 0.832 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.231382 | 0.636 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.109693 | 0.960 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.240868 | 0.618 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.250309 | 0.602 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.295492 | 0.529 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.324111 | 0.489 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 0.250401 | 0.601 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 0.164829 | 0.783 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.167466 | 0.776 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.120401 | 0.919 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.201413 | 0.696 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.164656 | 0.783 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.178187 | 0.749 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 0.114089 | 0.943 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.267374 | 0.573 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.165814 | 0.780 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.116165 | 0.935 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.116165 | 0.935 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.180090 | 0.745 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.203340 | 0.692 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.227642 | 0.643 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 0.134191 | 0.872 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 0.164829 | 0.783 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 0.194385 | 0.711 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.194385 | 0.711 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 0.222897 | 0.652 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 0.250401 | 0.601 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 0.250401 | 0.601 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 0.162852 | 0.788 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 0.240868 | 0.618 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 0.203340 | 0.692 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.203340 | 0.692 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.203340 | 0.692 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.212574 | 0.672 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.286778 | 0.542 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.272476 | 0.565 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.193215 | 0.714 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.146108 | 0.835 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.208406 | 0.681 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.277243 | 0.557 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.240868 | 0.618 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 0.241898 | 0.616 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.269539 | 0.569 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.194203 | 0.712 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.212574 | 0.672 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.212574 | 0.672 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.298659 | 0.525 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.246756 | 0.608 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.166783 | 0.778 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.170660 | 0.768 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 0.134191 | 0.872 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.222897 | 0.652 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 0.250401 | 0.601 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.250401 | 0.601 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.250401 | 0.601 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 0.125903 | 0.900 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 0.150317 | 0.823 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 0.175565 | 0.756 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 0.227655 | 0.643 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.176257 | 0.754 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.185172 | 0.732 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.185172 | 0.732 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.194203 | 0.712 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.126524 | 0.898 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.126524 | 0.898 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.153340 | 0.814 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.207155 | 0.684 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.132776 | 0.877 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 0.250401 | 0.601 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.162852 | 0.788 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.167466 | 0.776 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.240772 | 0.618 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.250309 | 0.602 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.125536 | 0.901 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.137577 | 0.861 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.150317 | 0.823 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 0.302528 | 0.519 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.214496 | 0.669 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.221897 | 0.654 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.231299 | 0.636 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.288925 | 0.539 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.278722 | 0.555 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.280631 | 0.552 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.260598 | 0.584 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.260598 | 0.584 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 0.302528 | 0.519 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.201413 | 0.696 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 0.307071 | 0.513 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.181876 | 0.740 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.262384 | 0.581 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 0.137990 | 0.860 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.280631 | 0.552 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 0.267374 | 0.573 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.239040 | 0.622 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.114962 | 0.939 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.122586 | 0.912 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.254525 | 0.594 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.300712 | 0.522 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.326163 | 0.487 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.245275 | 0.610 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.231299 | 0.636 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.131620 | 0.881 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 0.293868 | 0.532 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.298659 | 0.525 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.307071 | 0.513 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.280631 | 0.552 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.327937 | 0.484 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.327937 | 0.484 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.327937 | 0.484 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.333318 | 0.477 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.335523 | 0.474 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.337700 | 0.471 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.337700 | 0.471 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.340854 | 0.467 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.342321 | 0.466 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.345697 | 0.461 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.351036 | 0.455 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.351036 | 0.455 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 0.351036 | 0.455 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.351036 | 0.455 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 0.351036 | 0.455 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 0.351036 | 0.455 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.351036 | 0.455 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 0.351036 | 0.455 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 0.351036 | 0.455 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.351036 | 0.455 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.351036 | 0.455 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.351036 | 0.455 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 0.351036 | 0.455 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.351036 | 0.455 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.356655 | 0.448 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.359270 | 0.445 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.363712 | 0.439 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.366916 | 0.435 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.366916 | 0.435 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.370773 | 0.431 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.372108 | 0.429 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.372108 | 0.429 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.374012 | 0.427 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 0.374012 | 0.427 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.374012 | 0.427 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 0.374012 | 0.427 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 0.374012 | 0.427 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.374672 | 0.426 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.374672 | 0.426 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.376610 | 0.424 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.376610 | 0.424 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.376610 | 0.424 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.377832 | 0.423 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.382746 | 0.417 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.384842 | 0.415 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.384893 | 0.415 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.386274 | 0.413 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.395902 | 0.402 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.395902 | 0.402 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 0.396176 | 0.402 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 0.396176 | 0.402 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.396176 | 0.402 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 0.396176 | 0.402 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 0.396176 | 0.402 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.397462 | 0.401 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.399413 | 0.399 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.401003 | 0.397 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.405490 | 0.392 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.405490 | 0.392 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.409960 | 0.387 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.409960 | 0.387 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.414893 | 0.382 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.414893 | 0.382 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.417557 | 0.379 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.417557 | 0.379 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.417557 | 0.379 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 0.417557 | 0.379 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 0.417557 | 0.379 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 0.417557 | 0.379 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.417557 | 0.379 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 0.417557 | 0.379 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.422331 | 0.374 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.422331 | 0.374 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.424525 | 0.372 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.427090 | 0.369 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.431239 | 0.365 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.433965 | 0.363 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.433965 | 0.363 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.433965 | 0.363 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.434077 | 0.362 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.434566 | 0.362 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.434566 | 0.362 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.438182 | 0.358 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.438182 | 0.358 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.438182 | 0.358 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 0.438182 | 0.358 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 0.438182 | 0.358 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.438182 | 0.358 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.438182 | 0.358 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 0.438182 | 0.358 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 0.438182 | 0.358 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 0.438182 | 0.358 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 0.438182 | 0.358 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.438182 | 0.358 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.441320 | 0.355 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.443346 | 0.353 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.446660 | 0.350 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.446660 | 0.350 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.448401 | 0.348 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.452666 | 0.344 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.452666 | 0.344 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.452666 | 0.344 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 0.458077 | 0.339 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.458077 | 0.339 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.458077 | 0.339 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 0.458077 | 0.339 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.458077 | 0.339 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 0.458077 | 0.339 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.458608 | 0.339 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.458608 | 0.339 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.458608 | 0.339 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.458608 | 0.339 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.458608 | 0.339 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.458608 | 0.339 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.461821 | 0.336 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.461821 | 0.336 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.461921 | 0.335 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.461921 | 0.335 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.462426 | 0.335 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.470404 | 0.328 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.470404 | 0.328 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.471108 | 0.327 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.471108 | 0.327 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.473344 | 0.325 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.477269 | 0.321 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 0.477269 | 0.321 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.477269 | 0.321 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.477269 | 0.321 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.477269 | 0.321 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 0.477269 | 0.321 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.477269 | 0.321 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.477269 | 0.321 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 0.477269 | 0.321 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.479532 | 0.319 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.480223 | 0.319 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.482367 | 0.317 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.491841 | 0.308 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.493527 | 0.307 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.493527 | 0.307 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 0.495783 | 0.305 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.495783 | 0.305 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.495783 | 0.305 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.495783 | 0.305 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 0.495783 | 0.305 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 0.495783 | 0.305 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.495783 | 0.305 | 0 | 0 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | R-HSA-9837092 | 0.495783 | 0.305 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.495783 | 0.305 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.495783 | 0.305 | 0 | 0 |
| Immune System | R-HSA-168256 | 0.499546 | 0.301 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.500824 | 0.300 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.504847 | 0.297 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.504847 | 0.297 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.504847 | 0.297 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.504847 | 0.297 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 0.504847 | 0.297 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.507110 | 0.295 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.507110 | 0.295 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.513642 | 0.289 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.513642 | 0.289 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.513642 | 0.289 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.513642 | 0.289 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.513642 | 0.289 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 0.513642 | 0.289 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.513642 | 0.289 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 0.513642 | 0.289 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.513642 | 0.289 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.515882 | 0.287 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.516001 | 0.287 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.523331 | 0.281 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.526987 | 0.278 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.528153 | 0.277 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 0.530216 | 0.276 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.530725 | 0.275 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.530870 | 0.275 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.530870 | 0.275 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 0.530870 | 0.275 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 0.530870 | 0.275 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.530870 | 0.275 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 0.530870 | 0.275 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 0.530870 | 0.275 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.533255 | 0.273 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.533255 | 0.273 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.537803 | 0.269 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.537803 | 0.269 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.541794 | 0.266 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.541794 | 0.266 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.547488 | 0.262 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.547488 | 0.262 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.547488 | 0.262 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.547488 | 0.262 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.548448 | 0.261 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.550244 | 0.259 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.558600 | 0.253 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.558600 | 0.253 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.559720 | 0.252 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 0.563518 | 0.249 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.563518 | 0.249 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.563518 | 0.249 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 0.563518 | 0.249 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.563518 | 0.249 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.563518 | 0.249 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.563518 | 0.249 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.563518 | 0.249 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.563518 | 0.249 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 0.563518 | 0.249 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.563518 | 0.249 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.563518 | 0.249 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.566862 | 0.247 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.575029 | 0.240 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.575029 | 0.240 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.576008 | 0.240 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.578982 | 0.237 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 0.578982 | 0.237 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 0.578982 | 0.237 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.578982 | 0.237 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 0.578982 | 0.237 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 0.578982 | 0.237 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 0.578982 | 0.237 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.578982 | 0.237 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 0.578982 | 0.237 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.578982 | 0.237 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.579338 | 0.237 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.579874 | 0.237 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.580221 | 0.236 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.580221 | 0.236 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.580817 | 0.236 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.582208 | 0.235 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.582208 | 0.235 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.586394 | 0.232 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.589285 | 0.230 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.591072 | 0.228 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.591072 | 0.228 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.591721 | 0.228 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 0.593899 | 0.226 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 0.593899 | 0.226 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.593899 | 0.226 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 0.593899 | 0.226 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 0.593899 | 0.226 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.593899 | 0.226 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.593899 | 0.226 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 0.593899 | 0.226 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.594555 | 0.226 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.598945 | 0.223 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.601323 | 0.221 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.601323 | 0.221 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.601323 | 0.221 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.602791 | 0.220 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.608023 | 0.216 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.608265 | 0.216 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.608288 | 0.216 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.608288 | 0.216 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.608288 | 0.216 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 0.608288 | 0.216 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 0.608288 | 0.216 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.608288 | 0.216 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.608288 | 0.216 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.608288 | 0.216 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.608288 | 0.216 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 0.608288 | 0.216 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.608288 | 0.216 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 0.608288 | 0.216 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.608288 | 0.216 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.608650 | 0.216 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.613697 | 0.212 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.615020 | 0.211 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.617069 | 0.210 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.618070 | 0.209 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.619088 | 0.208 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.621963 | 0.206 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.622168 | 0.206 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.622168 | 0.206 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.622168 | 0.206 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.622168 | 0.206 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 0.622168 | 0.206 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.623263 | 0.205 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.627314 | 0.203 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.635557 | 0.197 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.635557 | 0.197 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.635557 | 0.197 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.635557 | 0.197 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.636383 | 0.196 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.636383 | 0.196 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.636383 | 0.196 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.636383 | 0.196 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.640468 | 0.194 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.640468 | 0.194 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.645278 | 0.190 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.645278 | 0.190 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.645278 | 0.190 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.645278 | 0.190 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 0.648473 | 0.188 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 0.648473 | 0.188 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.648473 | 0.188 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.648473 | 0.188 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.648473 | 0.188 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.648473 | 0.188 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.648473 | 0.188 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.654001 | 0.184 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 0.660931 | 0.180 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.660931 | 0.180 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.660931 | 0.180 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 0.660931 | 0.180 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.662552 | 0.179 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.662552 | 0.179 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.665236 | 0.177 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.670932 | 0.173 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.670932 | 0.173 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.670932 | 0.173 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 0.672949 | 0.172 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 0.672949 | 0.172 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 0.672949 | 0.172 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.675462 | 0.170 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.677018 | 0.169 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.678834 | 0.168 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.679142 | 0.168 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.684541 | 0.165 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.684541 | 0.165 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.684541 | 0.165 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.684541 | 0.165 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.684541 | 0.165 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.684541 | 0.165 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.684541 | 0.165 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 0.684541 | 0.165 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.687185 | 0.163 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.687835 | 0.163 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 0.692019 | 0.160 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.694296 | 0.158 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.694296 | 0.158 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.695061 | 0.158 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.695723 | 0.158 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.695723 | 0.158 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.695723 | 0.158 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.695723 | 0.158 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.695723 | 0.158 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.695723 | 0.158 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 0.695723 | 0.158 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.695723 | 0.158 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 0.695723 | 0.158 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.695723 | 0.158 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 0.695723 | 0.158 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.695723 | 0.158 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 0.695723 | 0.158 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.702773 | 0.153 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.702773 | 0.153 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.702773 | 0.153 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.702773 | 0.153 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.702773 | 0.153 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.702773 | 0.153 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.705443 | 0.152 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.705443 | 0.152 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.706510 | 0.151 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.706510 | 0.151 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.706510 | 0.151 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.706510 | 0.151 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.706510 | 0.151 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.706510 | 0.151 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.706510 | 0.151 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.710322 | 0.149 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.710322 | 0.149 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.710322 | 0.149 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.711025 | 0.148 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.711025 | 0.148 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.713506 | 0.147 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.713506 | 0.147 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.713506 | 0.147 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.716915 | 0.145 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 0.716915 | 0.145 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.717157 | 0.144 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.717711 | 0.144 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.719124 | 0.143 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.721607 | 0.142 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.721607 | 0.142 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.723187 | 0.141 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.726847 | 0.139 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 0.726951 | 0.138 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.726951 | 0.138 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.726951 | 0.138 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.726951 | 0.138 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.729117 | 0.137 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.730072 | 0.137 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.732012 | 0.135 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.732012 | 0.135 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.732527 | 0.135 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.736632 | 0.133 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.736632 | 0.133 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.736632 | 0.133 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.736632 | 0.133 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.736632 | 0.133 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.736632 | 0.133 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.737136 | 0.132 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.738929 | 0.131 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.742093 | 0.130 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 0.745971 | 0.127 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.751842 | 0.124 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.751842 | 0.124 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.751842 | 0.124 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 0.753749 | 0.123 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.754979 | 0.122 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.754979 | 0.122 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.754979 | 0.122 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 0.754979 | 0.122 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.754979 | 0.122 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 0.754979 | 0.122 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.758771 | 0.120 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.758771 | 0.120 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.759313 | 0.120 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.763668 | 0.117 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.763668 | 0.117 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.763668 | 0.117 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.766132 | 0.116 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.771263 | 0.113 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.772049 | 0.112 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.772049 | 0.112 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 0.772049 | 0.112 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.772049 | 0.112 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.772049 | 0.112 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.772049 | 0.112 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 0.772049 | 0.112 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.772049 | 0.112 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 0.772049 | 0.112 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.772049 | 0.112 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.777295 | 0.109 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.783031 | 0.106 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 0.783188 | 0.106 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.787933 | 0.104 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.787933 | 0.104 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.794563 | 0.100 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.794563 | 0.100 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 0.795455 | 0.099 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 0.795455 | 0.099 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 0.795455 | 0.099 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 0.795455 | 0.099 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.800051 | 0.097 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.801973 | 0.096 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.802124 | 0.096 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.802257 | 0.096 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.805409 | 0.094 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.805409 | 0.094 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.806486 | 0.093 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.809710 | 0.092 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.809710 | 0.092 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 0.809710 | 0.092 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 0.809710 | 0.092 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.809710 | 0.092 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.809710 | 0.092 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.810305 | 0.091 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.810912 | 0.091 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.810912 | 0.091 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.812190 | 0.090 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.815742 | 0.088 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.816461 | 0.088 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.816461 | 0.088 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.816461 | 0.088 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.816461 | 0.088 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.816461 | 0.088 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.816461 | 0.088 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 0.816461 | 0.088 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.816461 | 0.088 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.820722 | 0.086 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.822973 | 0.085 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.822973 | 0.085 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.822973 | 0.085 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.822973 | 0.085 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.822973 | 0.085 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.827771 | 0.082 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.829254 | 0.081 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.829254 | 0.081 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.829254 | 0.081 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 0.829254 | 0.081 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.830323 | 0.081 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.834947 | 0.078 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 0.835313 | 0.078 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 0.835313 | 0.078 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 0.835313 | 0.078 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.839555 | 0.076 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.841157 | 0.075 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.843856 | 0.074 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.846794 | 0.072 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.848145 | 0.072 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.850637 | 0.070 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.852232 | 0.069 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.852232 | 0.069 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.852232 | 0.069 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.852327 | 0.069 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.854181 | 0.068 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.856403 | 0.067 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.856403 | 0.067 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.857476 | 0.067 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.857476 | 0.067 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.857476 | 0.067 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.863824 | 0.064 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.863824 | 0.064 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.864373 | 0.063 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.865406 | 0.063 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.867415 | 0.062 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.867415 | 0.062 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.868994 | 0.061 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.872122 | 0.059 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.872122 | 0.059 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.873935 | 0.059 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.874172 | 0.058 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.875284 | 0.058 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.875284 | 0.058 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 0.875807 | 0.058 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.878774 | 0.056 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.879973 | 0.056 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.879973 | 0.056 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.879973 | 0.056 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.879973 | 0.056 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.881041 | 0.055 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.881041 | 0.055 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.882175 | 0.054 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.885264 | 0.053 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.885264 | 0.053 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.889338 | 0.051 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 0.890441 | 0.050 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.892176 | 0.050 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.894913 | 0.048 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.897891 | 0.047 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.900714 | 0.045 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.900790 | 0.045 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.901631 | 0.045 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.904241 | 0.044 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.905768 | 0.043 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.906361 | 0.043 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.907642 | 0.042 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.910923 | 0.041 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.910923 | 0.041 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.911637 | 0.040 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.911637 | 0.040 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.914087 | 0.039 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 0.914087 | 0.039 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.914087 | 0.039 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.914087 | 0.039 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.914087 | 0.039 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.914170 | 0.039 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.916635 | 0.038 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 0.917139 | 0.038 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.920083 | 0.036 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.920083 | 0.036 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.923635 | 0.034 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.930851 | 0.031 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.933308 | 0.030 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 0.933308 | 0.030 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.933308 | 0.030 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.933308 | 0.030 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.934087 | 0.030 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.934694 | 0.029 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.935678 | 0.029 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.935678 | 0.029 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.939692 | 0.027 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.941182 | 0.026 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.941458 | 0.026 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.942296 | 0.026 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.942296 | 0.026 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.942296 | 0.026 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.944348 | 0.025 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 0.945284 | 0.024 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.946465 | 0.024 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.946465 | 0.024 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.948235 | 0.023 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.948286 | 0.023 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.950075 | 0.022 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 0.954326 | 0.020 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.955214 | 0.020 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.956502 | 0.019 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.958343 | 0.018 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.959825 | 0.018 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.960100 | 0.018 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.960100 | 0.018 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.962701 | 0.017 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 0.963962 | 0.016 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.967968 | 0.014 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.968931 | 0.014 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.969111 | 0.014 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.969111 | 0.014 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.969946 | 0.013 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.972035 | 0.012 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.972035 | 0.012 | 0 | 0 |
| Disease | R-HSA-1643685 | 0.972147 | 0.012 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.975809 | 0.011 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.979075 | 0.009 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 0.979335 | 0.009 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.983725 | 0.007 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 0.983766 | 0.007 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.984894 | 0.007 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.985959 | 0.006 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.986777 | 0.006 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 0.988087 | 0.005 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 0.989543 | 0.005 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 0.990584 | 0.004 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 0.992676 | 0.003 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.993508 | 0.003 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.995858 | 0.002 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 0.996338 | 0.002 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.996595 | 0.001 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.996595 | 0.001 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.996595 | 0.001 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.996717 | 0.001 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.997455 | 0.001 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 0.997718 | 0.001 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 0.998689 | 0.001 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 0.998771 | 0.001 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 0.998838 | 0.001 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 0.999047 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 0.999264 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 0.999363 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 0.999501 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 0.999657 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 0.999781 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 0.999800 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 0.999980 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 0.999987 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 0.999997 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 0.999999 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| HSF1-dependent transactivation | R-HSA-3371571 | 9.281464e-14 | 13.032 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.565414e-13 | 12.805 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 3.278600e-12 | 11.484 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.278200e-11 | 10.369 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 4.832446e-11 | 10.316 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 3.976410e-10 | 9.401 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.103882e-09 | 8.957 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.140689e-09 | 8.669 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 3.346874e-08 | 7.475 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 5.993898e-08 | 7.222 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 5.925040e-08 | 7.227 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 5.011637e-07 | 6.300 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 5.438646e-07 | 6.265 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 6.197063e-07 | 6.208 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 6.420410e-07 | 6.192 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 3.303171e-06 | 5.481 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 6.179757e-06 | 5.209 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.173531e-05 | 4.931 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.073186e-05 | 4.969 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.192129e-05 | 4.924 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.173531e-05 | 4.931 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.673482e-05 | 4.776 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 2.809700e-05 | 4.551 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.762629e-05 | 4.559 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 3.259562e-05 | 4.487 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 3.767776e-05 | 4.424 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 3.648922e-05 | 4.438 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 4.618608e-05 | 4.335 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 6.368805e-05 | 4.196 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 7.233782e-05 | 4.141 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 6.952701e-05 | 4.158 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 8.039380e-05 | 4.095 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 9.841732e-05 | 4.007 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 9.783156e-05 | 4.010 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.036707e-04 | 3.984 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.182266e-04 | 3.927 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.293293e-04 | 3.888 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.961347e-04 | 3.707 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 2.340733e-04 | 3.631 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.641161e-04 | 3.578 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 2.877621e-04 | 3.541 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.397414e-04 | 3.469 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 3.634648e-04 | 3.440 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.769805e-04 | 3.424 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 4.458155e-04 | 3.351 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 5.758819e-04 | 3.240 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 5.610026e-04 | 3.251 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 7.130272e-04 | 3.147 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 8.024931e-04 | 3.096 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 8.957310e-04 | 3.048 | 0 | 0 |
| Protein folding | R-HSA-391251 | 9.652415e-04 | 3.015 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.778289e-04 | 3.010 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.084643e-03 | 2.965 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 1.061740e-03 | 2.974 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.171699e-03 | 2.931 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.647629e-03 | 2.783 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.760395e-03 | 2.754 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.941582e-03 | 2.712 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.946496e-03 | 2.711 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.133952e-03 | 2.671 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.167909e-03 | 2.664 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.462701e-03 | 2.609 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 2.466874e-03 | 2.608 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 2.466874e-03 | 2.608 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 2.470520e-03 | 2.607 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 2.695684e-03 | 2.569 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 3.062862e-03 | 2.514 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 3.230748e-03 | 2.491 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 3.243049e-03 | 2.489 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 3.752960e-03 | 2.426 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 3.852788e-03 | 2.414 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.120927e-03 | 2.385 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.135807e-03 | 2.383 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.302124e-03 | 2.366 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 4.830309e-03 | 2.316 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 4.979385e-03 | 2.303 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 4.979385e-03 | 2.303 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 5.100561e-03 | 2.292 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.512292e-03 | 2.259 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 5.260720e-03 | 2.279 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 5.347977e-03 | 2.272 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 5.801759e-03 | 2.236 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 5.801759e-03 | 2.236 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 5.738085e-03 | 2.241 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.946289e-03 | 2.226 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 5.737580e-03 | 2.241 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 5.801759e-03 | 2.236 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 6.449735e-03 | 2.190 | 0 | 0 |
| Kinesins | R-HSA-983189 | 6.472628e-03 | 2.189 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 6.477821e-03 | 2.189 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 6.675929e-03 | 2.175 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 7.040415e-03 | 2.152 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 6.658496e-03 | 2.177 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 7.050700e-03 | 2.152 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 7.379923e-03 | 2.132 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 7.477408e-03 | 2.126 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 7.630346e-03 | 2.117 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 8.040968e-03 | 2.095 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.055743e-03 | 2.043 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 8.471975e-03 | 2.072 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 9.120568e-03 | 2.040 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 9.650215e-03 | 2.015 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 9.650215e-03 | 2.015 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.653487e-03 | 2.015 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 1.035756e-02 | 1.985 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.159781e-02 | 1.936 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 1.370889e-02 | 1.863 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.370889e-02 | 1.863 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 1.399607e-02 | 1.854 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.448637e-02 | 1.839 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 1.484607e-02 | 1.828 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.498825e-02 | 1.824 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.529095e-02 | 1.816 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.696023e-02 | 1.771 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.710777e-02 | 1.767 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.557170e-02 | 1.808 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.636605e-02 | 1.786 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 1.724335e-02 | 1.763 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 1.724335e-02 | 1.763 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.784692e-02 | 1.748 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.877690e-02 | 1.726 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.889626e-02 | 1.724 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.925113e-02 | 1.716 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.025936e-02 | 1.693 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 2.258282e-02 | 1.646 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.207570e-02 | 1.656 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.207570e-02 | 1.656 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.207570e-02 | 1.656 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.207570e-02 | 1.656 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.052553e-02 | 1.688 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.352198e-02 | 1.629 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 2.356945e-02 | 1.628 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 2.386287e-02 | 1.622 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.574441e-02 | 1.589 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 2.574441e-02 | 1.589 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 2.578949e-02 | 1.589 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 2.729876e-02 | 1.564 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.242315e-02 | 1.489 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.104268e-02 | 1.508 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 3.257076e-02 | 1.487 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 2.915437e-02 | 1.535 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.982233e-02 | 1.525 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.016639e-02 | 1.520 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 3.280323e-02 | 1.484 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 3.280323e-02 | 1.484 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.334628e-02 | 1.477 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 3.424189e-02 | 1.465 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 3.424805e-02 | 1.465 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.424805e-02 | 1.465 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.435528e-02 | 1.464 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 3.435528e-02 | 1.464 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 3.547192e-02 | 1.450 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 4.085461e-02 | 1.389 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 3.662572e-02 | 1.436 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.997876e-02 | 1.398 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 4.085461e-02 | 1.389 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 3.814885e-02 | 1.419 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 4.063307e-02 | 1.391 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 3.997876e-02 | 1.398 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 4.010301e-02 | 1.397 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 4.169185e-02 | 1.380 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 4.267223e-02 | 1.370 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 4.387493e-02 | 1.358 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 4.438231e-02 | 1.353 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 4.640583e-02 | 1.333 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 4.640583e-02 | 1.333 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 4.661473e-02 | 1.331 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 4.751087e-02 | 1.323 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 4.752896e-02 | 1.323 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 4.797658e-02 | 1.319 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 4.831692e-02 | 1.316 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 5.008409e-02 | 1.300 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 5.221799e-02 | 1.282 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 5.221799e-02 | 1.282 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 5.221799e-02 | 1.282 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 5.228301e-02 | 1.282 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 6.065143e-02 | 1.217 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 6.150509e-02 | 1.211 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 6.277140e-02 | 1.202 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 6.065143e-02 | 1.217 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 5.836310e-02 | 1.234 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 6.066210e-02 | 1.217 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 6.483215e-02 | 1.188 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 6.483215e-02 | 1.188 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 6.483215e-02 | 1.188 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 7.630100e-02 | 1.117 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 7.630100e-02 | 1.117 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 7.630100e-02 | 1.117 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 7.630100e-02 | 1.117 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 7.630100e-02 | 1.117 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 7.630100e-02 | 1.117 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.683078e-02 | 1.114 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 6.613688e-02 | 1.180 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 7.028701e-02 | 1.153 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 6.641708e-02 | 1.178 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 7.152658e-02 | 1.146 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 6.641708e-02 | 1.178 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 7.152658e-02 | 1.146 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 7.335668e-02 | 1.135 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 7.532817e-02 | 1.123 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 7.630100e-02 | 1.117 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.709616e-02 | 1.113 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 7.870215e-02 | 1.104 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 6.722070e-02 | 1.172 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 6.621407e-02 | 1.179 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 7.342374e-02 | 1.134 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 7.641264e-02 | 1.117 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.732079e-02 | 1.172 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 7.824587e-02 | 1.107 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 6.627776e-02 | 1.179 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 7.870215e-02 | 1.104 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 6.649670e-02 | 1.177 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 6.890913e-02 | 1.162 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 8.038263e-02 | 1.095 | 0 | 0 |
| Defective SLC34A2 causes PALM | R-HSA-5687583 | 1.122430e-01 | 0.950 | 0 | 0 |
| Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM) | R-HSA-5619045 | 1.122430e-01 | 0.950 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 1.122430e-01 | 0.950 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 1.122430e-01 | 0.950 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.467886e-01 | 0.833 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 1.467886e-01 | 0.833 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.467886e-01 | 0.833 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.467886e-01 | 0.833 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.467886e-01 | 0.833 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 1.799919e-01 | 0.745 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 8.301190e-02 | 1.081 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 8.301190e-02 | 1.081 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 2.119050e-01 | 0.674 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 2.119050e-01 | 0.674 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 2.425780e-01 | 0.615 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 2.425780e-01 | 0.615 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 2.425780e-01 | 0.615 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 2.425780e-01 | 0.615 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 2.720590e-01 | 0.565 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.720590e-01 | 0.565 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 2.720590e-01 | 0.565 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.720590e-01 | 0.565 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 8.608153e-02 | 1.065 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 3.003942e-01 | 0.522 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 3.003942e-01 | 0.522 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 3.003942e-01 | 0.522 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 3.003942e-01 | 0.522 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 3.003942e-01 | 0.522 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 3.003942e-01 | 0.522 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 3.003942e-01 | 0.522 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 3.003942e-01 | 0.522 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.747104e-01 | 0.758 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 1.747104e-01 | 0.758 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 1.747104e-01 | 0.758 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.888778e-01 | 0.724 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.888778e-01 | 0.724 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.888778e-01 | 0.724 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 3.276281e-01 | 0.485 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 3.276281e-01 | 0.485 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.276281e-01 | 0.485 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 3.276281e-01 | 0.485 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 3.276281e-01 | 0.485 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 8.801021e-02 | 1.055 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 2.031934e-01 | 0.692 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 1.449185e-01 | 0.839 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 2.176244e-01 | 0.662 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.176244e-01 | 0.662 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 3.538035e-01 | 0.451 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 3.538035e-01 | 0.451 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 3.538035e-01 | 0.451 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 3.538035e-01 | 0.451 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 3.538035e-01 | 0.451 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 1.541987e-01 | 0.812 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.125448e-01 | 0.949 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 2.321402e-01 | 0.634 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 1.636593e-01 | 0.786 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.191060e-01 | 0.924 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.311697e-02 | 1.031 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.258284e-01 | 0.900 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.732875e-01 | 0.761 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 2.467124e-01 | 0.608 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 3.789614e-01 | 0.421 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 3.789614e-01 | 0.421 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 9.808899e-02 | 1.008 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 9.808899e-02 | 1.008 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.830708e-01 | 0.737 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.830708e-01 | 0.737 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.397362e-01 | 0.855 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 1.137840e-01 | 0.944 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.030531e-01 | 0.692 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.030531e-01 | 0.692 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 4.031413e-01 | 0.395 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 4.031413e-01 | 0.395 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 4.031413e-01 | 0.395 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.616724e-01 | 0.791 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.616724e-01 | 0.791 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 2.132276e-01 | 0.671 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.132276e-01 | 0.671 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 2.132276e-01 | 0.671 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.305990e-01 | 0.884 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.305990e-01 | 0.884 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.692483e-01 | 0.771 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.905137e-01 | 0.537 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.905137e-01 | 0.537 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 2.235087e-01 | 0.651 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 3.050673e-01 | 0.516 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 3.050673e-01 | 0.516 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.514177e-01 | 0.820 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.170584e-01 | 0.663 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 3.483188e-01 | 0.458 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 3.483188e-01 | 0.458 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 3.483188e-01 | 0.458 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 2.868022e-01 | 0.542 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 2.215741e-01 | 0.654 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.766538e-01 | 0.424 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 2.671750e-01 | 0.573 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 2.030531e-01 | 0.692 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 2.759225e-01 | 0.559 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 2.235087e-01 | 0.651 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.218681e-01 | 0.654 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.511151e-01 | 0.821 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.030531e-01 | 0.692 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 9.302652e-02 | 1.031 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.652811e-01 | 0.576 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.364850e-01 | 0.865 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 3.830312e-01 | 0.417 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 2.605569e-01 | 0.584 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 1.325769e-01 | 0.878 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.092889e-01 | 0.679 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.747104e-01 | 0.758 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 2.031934e-01 | 0.692 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 2.759225e-01 | 0.559 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 3.082606e-01 | 0.511 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 2.766672e-01 | 0.558 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.616724e-01 | 0.791 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 8.801021e-02 | 1.055 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 3.906309e-01 | 0.408 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 1.616724e-01 | 0.791 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 9.761894e-02 | 1.010 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 9.761894e-02 | 1.010 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 1.158266e-01 | 0.936 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 2.759225e-01 | 0.559 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 3.339867e-01 | 0.476 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 2.761155e-01 | 0.559 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 3.766538e-01 | 0.424 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.305990e-01 | 0.884 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.258284e-01 | 0.900 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.486743e-01 | 0.828 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 2.759225e-01 | 0.559 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 8.232649e-02 | 1.084 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.483188e-01 | 0.458 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.944499e-01 | 0.711 | 1 | 1 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 3.625456e-01 | 0.441 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 1.074308e-01 | 0.969 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 2.425780e-01 | 0.615 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 2.425780e-01 | 0.615 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 2.425780e-01 | 0.615 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.176244e-01 | 0.662 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 3.538035e-01 | 0.451 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 1.258284e-01 | 0.900 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 1.258284e-01 | 0.900 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.732875e-01 | 0.761 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 3.789614e-01 | 0.421 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 4.031413e-01 | 0.395 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 2.235087e-01 | 0.651 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 3.483188e-01 | 0.458 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 3.625456e-01 | 0.441 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.190137e-01 | 0.496 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 3.297710e-01 | 0.482 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.327070e-01 | 0.877 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 1.542246e-01 | 0.812 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.512644e-01 | 0.454 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 1.732875e-01 | 0.761 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 3.107600e-01 | 0.508 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.625456e-01 | 0.441 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.803467e-01 | 0.744 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 1.799919e-01 | 0.745 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 2.425780e-01 | 0.615 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.747104e-01 | 0.758 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 2.467124e-01 | 0.608 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.007131e-01 | 0.697 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.287104e-01 | 0.641 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 9.808899e-02 | 1.008 | 1 | 1 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 1.469106e-01 | 0.833 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 3.789614e-01 | 0.421 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.321402e-01 | 0.634 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 2.030531e-01 | 0.692 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 3.352363e-01 | 0.475 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 2.030531e-01 | 0.692 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 1.122430e-01 | 0.950 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 1.122430e-01 | 0.950 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 1.122430e-01 | 0.950 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 1.467886e-01 | 0.833 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 1.467886e-01 | 0.833 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 1.799919e-01 | 0.745 | 0 | 0 |
| Type II Na+/Pi cotransporters | R-HSA-427589 | 1.799919e-01 | 0.745 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 8.301190e-02 | 1.081 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 2.119050e-01 | 0.674 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.202715e-01 | 0.920 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 1.334650e-01 | 0.875 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 2.720590e-01 | 0.565 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 1.469646e-01 | 0.833 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 3.003942e-01 | 0.522 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 3.003942e-01 | 0.522 | 0 | 0 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | R-HSA-9837092 | 1.747104e-01 | 0.758 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 3.276281e-01 | 0.485 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 3.538035e-01 | 0.451 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 2.321402e-01 | 0.634 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 2.321402e-01 | 0.634 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 3.789614e-01 | 0.421 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 1.031922e-01 | 0.986 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 4.031413e-01 | 0.395 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 4.031413e-01 | 0.395 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 1.616724e-01 | 0.791 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.905137e-01 | 0.537 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.195641e-01 | 0.495 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 2.088397e-01 | 0.680 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 3.339867e-01 | 0.476 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 3.339867e-01 | 0.476 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.339867e-01 | 0.476 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.339867e-01 | 0.476 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 2.593241e-01 | 0.586 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.941910e-01 | 0.531 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 3.512644e-01 | 0.454 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 3.385051e-01 | 0.470 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.960248e-01 | 0.402 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.094823e-01 | 0.961 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.304297e-01 | 0.885 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 3.352363e-01 | 0.475 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 1.358314e-01 | 0.867 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 3.483188e-01 | 0.458 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 1.612075e-01 | 0.793 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 2.431774e-01 | 0.614 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.337983e-01 | 0.874 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.191060e-01 | 0.924 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 2.338846e-01 | 0.631 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.930919e-01 | 0.533 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 3.003942e-01 | 0.522 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 3.538035e-01 | 0.451 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.339867e-01 | 0.476 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.297710e-01 | 0.482 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.048496e-01 | 0.516 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 9.311697e-02 | 1.031 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 2.145075e-01 | 0.669 | 1 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.258284e-01 | 0.900 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 2.720590e-01 | 0.565 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.276281e-01 | 0.485 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.176244e-01 | 0.662 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.030531e-01 | 0.692 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 4.031413e-01 | 0.395 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 4.031413e-01 | 0.395 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 1.616724e-01 | 0.791 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 2.132276e-01 | 0.671 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 1.692483e-01 | 0.771 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 3.050673e-01 | 0.516 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.919100e-01 | 0.407 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 3.619847e-01 | 0.441 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 9.311697e-02 | 1.031 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 2.467124e-01 | 0.608 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.164928e-01 | 0.934 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 3.741376e-01 | 0.427 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 2.467124e-01 | 0.608 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 1.122430e-01 | 0.950 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 1.467886e-01 | 0.833 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 1.467886e-01 | 0.833 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 1.334650e-01 | 0.875 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 2.720590e-01 | 0.565 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 3.276281e-01 | 0.485 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 3.538035e-01 | 0.451 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 3.538035e-01 | 0.451 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.125448e-01 | 0.949 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 2.467124e-01 | 0.608 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 3.789614e-01 | 0.421 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.789614e-01 | 0.421 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 3.789614e-01 | 0.421 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 1.929968e-01 | 0.714 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 2.759225e-01 | 0.559 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.031413e-01 | 0.395 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 2.338846e-01 | 0.631 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 2.338846e-01 | 0.631 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 3.082606e-01 | 0.511 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 3.082606e-01 | 0.511 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 1.764869e-01 | 0.753 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 2.941910e-01 | 0.531 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.467124e-01 | 0.608 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.625125e-01 | 0.789 | 1 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 3.776975e-01 | 0.423 | 1 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.679702e-01 | 0.572 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 9.387814e-02 | 1.027 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 3.538035e-01 | 0.451 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 3.789614e-01 | 0.421 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.381664e-01 | 0.860 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 3.726772e-01 | 0.429 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 9.387814e-02 | 1.027 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.727858e-01 | 0.564 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 1.607267e-01 | 0.794 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 1.125448e-01 | 0.949 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 2.548763e-01 | 0.594 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.870106e-01 | 0.728 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 3.030069e-01 | 0.519 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 3.485971e-01 | 0.458 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 3.184475e-01 | 0.497 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.940399e-01 | 0.532 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.761155e-01 | 0.559 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 2.754169e-01 | 0.560 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.144374e-01 | 0.669 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.092889e-01 | 0.679 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.098576e-01 | 0.959 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 2.088397e-01 | 0.680 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.468961e-01 | 0.833 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.468961e-01 | 0.833 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 1.397362e-01 | 0.855 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 2.030531e-01 | 0.692 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.390401e-01 | 0.622 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 2.425780e-01 | 0.615 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.202715e-01 | 0.920 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 2.720590e-01 | 0.565 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.003942e-01 | 0.522 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 1.747104e-01 | 0.758 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 1.888778e-01 | 0.724 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.276281e-01 | 0.485 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 3.276281e-01 | 0.485 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.276281e-01 | 0.485 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 3.276281e-01 | 0.485 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 8.232649e-02 | 1.084 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 2.031934e-01 | 0.692 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 4.031413e-01 | 0.395 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 4.031413e-01 | 0.395 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.616724e-01 | 0.791 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.158266e-01 | 0.936 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 2.443442e-01 | 0.612 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 2.548763e-01 | 0.594 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 2.548763e-01 | 0.594 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.665974e-01 | 0.778 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.711641e-01 | 0.767 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.408684e-01 | 0.618 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 2.835562e-01 | 0.547 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 3.649316e-01 | 0.438 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.449185e-01 | 0.839 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 3.625456e-01 | 0.441 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 2.990099e-01 | 0.524 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 1.830708e-01 | 0.737 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.653086e-01 | 0.576 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.540634e-01 | 0.812 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 3.352363e-01 | 0.475 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.032923e-01 | 0.692 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 1.469646e-01 | 0.833 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 1.888778e-01 | 0.724 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 2.176244e-01 | 0.662 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.389526e-01 | 0.857 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.873812e-01 | 0.412 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.546372e-01 | 0.811 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.941910e-01 | 0.531 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 9.115828e-02 | 1.040 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.789614e-01 | 0.421 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.585268e-01 | 0.445 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.939508e-01 | 0.405 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.425780e-01 | 0.615 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 1.202715e-01 | 0.920 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.720590e-01 | 0.565 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 3.003942e-01 | 0.522 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 1.747104e-01 | 0.758 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 3.276281e-01 | 0.485 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 2.176244e-01 | 0.662 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.789614e-01 | 0.421 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.789614e-01 | 0.421 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 3.789614e-01 | 0.421 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.789614e-01 | 0.421 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 2.759225e-01 | 0.559 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 2.132276e-01 | 0.671 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 2.235087e-01 | 0.651 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 2.235087e-01 | 0.651 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 3.050673e-01 | 0.516 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.926846e-01 | 0.715 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.654702e-01 | 0.576 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 3.339867e-01 | 0.476 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 3.082606e-01 | 0.511 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 3.082606e-01 | 0.511 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 2.707041e-01 | 0.568 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 1.325434e-01 | 0.878 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 2.935761e-01 | 0.532 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 3.833348e-01 | 0.416 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.792868e-01 | 0.746 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.929968e-01 | 0.714 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 8.801021e-02 | 1.055 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 2.975204e-01 | 0.526 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.256273e-01 | 0.901 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 3.833348e-01 | 0.416 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 2.941910e-01 | 0.531 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 3.474128e-01 | 0.459 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.747104e-01 | 0.758 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.888778e-01 | 0.724 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.031934e-01 | 0.692 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.031934e-01 | 0.692 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 3.789614e-01 | 0.421 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 2.613146e-01 | 0.583 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.031413e-01 | 0.395 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.868022e-01 | 0.542 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 2.975204e-01 | 0.526 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 3.297710e-01 | 0.482 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 3.906309e-01 | 0.408 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.966234e-01 | 0.706 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 3.416326e-01 | 0.466 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 1.737741e-01 | 0.760 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 2.225644e-01 | 0.653 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.507345e-01 | 0.601 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.747478e-01 | 0.561 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.483188e-01 | 0.458 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.111236e-01 | 0.954 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.202715e-01 | 0.920 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 8.801021e-02 | 1.055 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 1.732875e-01 | 0.761 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 2.467124e-01 | 0.608 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 3.789614e-01 | 0.421 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.050673e-01 | 0.516 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 2.654702e-01 | 0.576 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 2.761155e-01 | 0.559 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 2.975204e-01 | 0.526 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 3.625456e-01 | 0.441 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 3.405240e-01 | 0.468 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 3.512644e-01 | 0.454 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 2.729044e-01 | 0.564 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 2.605569e-01 | 0.584 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.457793e-01 | 0.609 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 3.297710e-01 | 0.482 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.443442e-01 | 0.612 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 3.741376e-01 | 0.427 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.929968e-01 | 0.714 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 3.766538e-01 | 0.424 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 2.170584e-01 | 0.663 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 2.321402e-01 | 0.634 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 3.820710e-01 | 0.418 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.362458e-01 | 0.866 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.761155e-01 | 0.559 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 8.232649e-02 | 1.084 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 2.759225e-01 | 0.559 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 3.195641e-01 | 0.495 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 2.868022e-01 | 0.542 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 2.075142e-01 | 0.683 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 8.539074e-02 | 1.069 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.216086e-01 | 0.654 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 3.625456e-01 | 0.441 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 3.919100e-01 | 0.407 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 2.941910e-01 | 0.531 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 1.469646e-01 | 0.833 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 3.538035e-01 | 0.451 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.061499e-01 | 0.974 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.905137e-01 | 0.537 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.321402e-01 | 0.634 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.467124e-01 | 0.608 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.067379e-01 | 0.972 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 3.512644e-01 | 0.454 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 3.512644e-01 | 0.454 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 2.338846e-01 | 0.631 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 8.106400e-02 | 1.091 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 3.830312e-01 | 0.417 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 4.031413e-01 | 0.395 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 3.910177e-01 | 0.408 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 2.761155e-01 | 0.559 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 3.651668e-01 | 0.438 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 3.512644e-01 | 0.454 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 9.662269e-02 | 1.015 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 3.939508e-01 | 0.405 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 3.939508e-01 | 0.405 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 9.942390e-02 | 1.003 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 1.692483e-01 | 0.771 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 4.037829e-01 | 0.394 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 4.044658e-01 | 0.393 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 4.044658e-01 | 0.393 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 4.044658e-01 | 0.393 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 4.044658e-01 | 0.393 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 4.049905e-01 | 0.393 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 4.096071e-01 | 0.388 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 4.102031e-01 | 0.387 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 4.107838e-01 | 0.386 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 4.115290e-01 | 0.386 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.150321e-01 | 0.382 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 4.180067e-01 | 0.379 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 4.181484e-01 | 0.379 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 4.181484e-01 | 0.379 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 4.181484e-01 | 0.379 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 4.190249e-01 | 0.378 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 4.192605e-01 | 0.378 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.243970e-01 | 0.372 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 4.254854e-01 | 0.371 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 4.254854e-01 | 0.371 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 4.254854e-01 | 0.371 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 4.263812e-01 | 0.370 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 4.263812e-01 | 0.370 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 4.263812e-01 | 0.370 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.263812e-01 | 0.370 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.269746e-01 | 0.370 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 4.271966e-01 | 0.369 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.316697e-01 | 0.365 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 4.316697e-01 | 0.365 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 4.316697e-01 | 0.365 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.358730e-01 | 0.361 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 4.358730e-01 | 0.361 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.358730e-01 | 0.361 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 4.358730e-01 | 0.361 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 4.446487e-01 | 0.352 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 4.446487e-01 | 0.352 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 4.446487e-01 | 0.352 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 4.450214e-01 | 0.352 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 4.450214e-01 | 0.352 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 4.450214e-01 | 0.352 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 4.466985e-01 | 0.350 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 4.484116e-01 | 0.348 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 4.487176e-01 | 0.348 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 4.487176e-01 | 0.348 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 4.487176e-01 | 0.348 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 4.487176e-01 | 0.348 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 4.487176e-01 | 0.348 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 4.487176e-01 | 0.348 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 4.487176e-01 | 0.348 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 4.487176e-01 | 0.348 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 4.524475e-01 | 0.344 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 4.564302e-01 | 0.341 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 4.564302e-01 | 0.341 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.569164e-01 | 0.340 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 4.576054e-01 | 0.340 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 4.581963e-01 | 0.339 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 4.581963e-01 | 0.339 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 4.581963e-01 | 0.339 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 4.581963e-01 | 0.339 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 4.581963e-01 | 0.339 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.619355e-01 | 0.335 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 4.651943e-01 | 0.332 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.665903e-01 | 0.331 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.665903e-01 | 0.331 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.665903e-01 | 0.331 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 4.701855e-01 | 0.328 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 4.701855e-01 | 0.328 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.701855e-01 | 0.328 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.701855e-01 | 0.328 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 4.701855e-01 | 0.328 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 4.701855e-01 | 0.328 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 4.701855e-01 | 0.328 | 0 | 0 |
| Proline catabolism | R-HSA-70688 | 4.701855e-01 | 0.328 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 4.701855e-01 | 0.328 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 4.701855e-01 | 0.328 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 4.701855e-01 | 0.328 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 4.701855e-01 | 0.328 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 4.701855e-01 | 0.328 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 4.701855e-01 | 0.328 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 4.701855e-01 | 0.328 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 4.701855e-01 | 0.328 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 4.701855e-01 | 0.328 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 4.701855e-01 | 0.328 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.705536e-01 | 0.327 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 4.711879e-01 | 0.327 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 4.790313e-01 | 0.320 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 4.802733e-01 | 0.319 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 4.809803e-01 | 0.318 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 4.809803e-01 | 0.318 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 4.809803e-01 | 0.318 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.815653e-01 | 0.317 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 4.839906e-01 | 0.315 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 4.839906e-01 | 0.315 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 4.839906e-01 | 0.315 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 4.839906e-01 | 0.315 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 4.839906e-01 | 0.315 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 4.839906e-01 | 0.315 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 4.839906e-01 | 0.315 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.866512e-01 | 0.313 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 4.875001e-01 | 0.312 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 4.877591e-01 | 0.312 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 4.877591e-01 | 0.312 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 4.908187e-01 | 0.309 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 4.908187e-01 | 0.309 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 4.908187e-01 | 0.309 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 4.908187e-01 | 0.309 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 4.908187e-01 | 0.309 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 4.908187e-01 | 0.309 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 4.908187e-01 | 0.309 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 4.908187e-01 | 0.309 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 4.908187e-01 | 0.309 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 4.908187e-01 | 0.309 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 4.908187e-01 | 0.309 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 4.932511e-01 | 0.307 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 4.938655e-01 | 0.306 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 4.959125e-01 | 0.305 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 5.012421e-01 | 0.300 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 5.026127e-01 | 0.299 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 5.026127e-01 | 0.299 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 5.035504e-01 | 0.298 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 5.062475e-01 | 0.296 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 5.063405e-01 | 0.296 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 5.063405e-01 | 0.296 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 5.063405e-01 | 0.296 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 5.063405e-01 | 0.296 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 5.090097e-01 | 0.293 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 5.090097e-01 | 0.293 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 5.090097e-01 | 0.293 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 5.106495e-01 | 0.292 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 5.106495e-01 | 0.292 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 5.106495e-01 | 0.292 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 5.106495e-01 | 0.292 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 5.106495e-01 | 0.292 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 5.106495e-01 | 0.292 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 5.106495e-01 | 0.292 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.106495e-01 | 0.292 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 5.106495e-01 | 0.292 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 5.124006e-01 | 0.290 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 5.124006e-01 | 0.290 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.160370e-01 | 0.287 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.160370e-01 | 0.287 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 5.172962e-01 | 0.286 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 5.172962e-01 | 0.286 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 5.172962e-01 | 0.286 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 5.207849e-01 | 0.283 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 5.212182e-01 | 0.283 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 5.212182e-01 | 0.283 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 5.212182e-01 | 0.283 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.212182e-01 | 0.283 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 5.297092e-01 | 0.276 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 5.297092e-01 | 0.276 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 5.297092e-01 | 0.276 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 5.297092e-01 | 0.276 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 5.297092e-01 | 0.276 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 5.297092e-01 | 0.276 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.306943e-01 | 0.275 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 5.317949e-01 | 0.274 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 5.332216e-01 | 0.273 | 0 | 0 |
| Depurination | R-HSA-73927 | 5.332216e-01 | 0.273 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 5.332216e-01 | 0.273 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.351181e-01 | 0.272 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 5.353861e-01 | 0.271 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 5.370391e-01 | 0.270 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 5.417633e-01 | 0.266 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 5.444973e-01 | 0.264 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 5.450175e-01 | 0.264 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 5.450175e-01 | 0.264 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 5.450616e-01 | 0.264 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 5.480276e-01 | 0.261 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 5.480276e-01 | 0.261 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 5.480276e-01 | 0.261 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.480276e-01 | 0.261 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 5.480276e-01 | 0.261 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 5.480276e-01 | 0.261 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.501327e-01 | 0.260 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 5.530116e-01 | 0.257 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.530116e-01 | 0.257 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.531673e-01 | 0.257 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 5.537655e-01 | 0.257 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 5.566038e-01 | 0.254 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.566038e-01 | 0.254 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.566038e-01 | 0.254 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 5.566038e-01 | 0.254 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 5.566038e-01 | 0.254 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.566038e-01 | 0.254 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 5.656336e-01 | 0.247 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 5.656336e-01 | 0.247 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 5.656336e-01 | 0.247 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 5.656336e-01 | 0.247 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 5.656336e-01 | 0.247 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 5.656336e-01 | 0.247 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 5.656336e-01 | 0.247 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 5.656336e-01 | 0.247 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 5.656336e-01 | 0.247 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 5.656336e-01 | 0.247 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 5.656336e-01 | 0.247 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.665240e-01 | 0.247 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 5.679789e-01 | 0.246 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 5.679789e-01 | 0.246 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 5.686876e-01 | 0.245 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.693559e-01 | 0.245 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 5.740533e-01 | 0.241 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.764101e-01 | 0.239 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 5.791417e-01 | 0.237 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 5.791417e-01 | 0.237 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 5.791417e-01 | 0.237 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 5.791417e-01 | 0.237 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 5.791417e-01 | 0.237 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 5.791417e-01 | 0.237 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 5.808839e-01 | 0.236 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.808839e-01 | 0.236 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.825548e-01 | 0.235 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.825548e-01 | 0.235 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 5.825548e-01 | 0.235 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 5.825548e-01 | 0.235 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 5.825548e-01 | 0.235 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 5.825548e-01 | 0.235 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 5.825548e-01 | 0.235 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 5.825548e-01 | 0.235 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 5.825548e-01 | 0.235 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 5.838361e-01 | 0.234 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 5.876894e-01 | 0.231 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 5.876894e-01 | 0.231 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 5.900915e-01 | 0.229 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 5.900915e-01 | 0.229 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 5.900915e-01 | 0.229 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 5.900915e-01 | 0.229 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 5.900915e-01 | 0.229 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 5.900915e-01 | 0.229 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 5.900915e-01 | 0.229 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 5.983735e-01 | 0.223 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.983735e-01 | 0.223 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.983735e-01 | 0.223 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 5.988178e-01 | 0.223 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 5.988178e-01 | 0.223 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 5.988178e-01 | 0.223 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 5.988178e-01 | 0.223 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 5.988178e-01 | 0.223 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 5.988178e-01 | 0.223 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.001784e-01 | 0.222 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 6.008279e-01 | 0.221 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 6.008279e-01 | 0.221 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 6.064980e-01 | 0.217 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 6.069372e-01 | 0.217 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 6.069372e-01 | 0.217 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 6.087996e-01 | 0.216 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 6.113509e-01 | 0.214 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 6.144481e-01 | 0.212 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.144481e-01 | 0.212 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 6.144481e-01 | 0.212 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 6.144481e-01 | 0.212 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 6.144481e-01 | 0.212 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 6.144481e-01 | 0.212 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 6.144481e-01 | 0.212 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 6.144481e-01 | 0.212 | 0 | 0 |
| Translation | R-HSA-72766 | 6.145728e-01 | 0.211 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 6.153787e-01 | 0.211 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 6.153787e-01 | 0.211 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 6.214231e-01 | 0.207 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 6.216609e-01 | 0.206 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 6.216609e-01 | 0.206 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 6.216609e-01 | 0.206 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 6.216609e-01 | 0.206 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 6.236971e-01 | 0.205 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 6.281885e-01 | 0.202 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 6.294704e-01 | 0.201 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.294704e-01 | 0.201 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 6.294704e-01 | 0.201 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 6.294704e-01 | 0.201 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 6.294704e-01 | 0.201 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 6.294704e-01 | 0.201 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 6.294704e-01 | 0.201 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 6.317584e-01 | 0.199 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 6.317584e-01 | 0.199 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 6.317584e-01 | 0.199 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 6.317584e-01 | 0.199 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 6.317584e-01 | 0.199 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.334658e-01 | 0.198 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 6.352467e-01 | 0.197 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.399616e-01 | 0.194 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 6.399616e-01 | 0.194 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 6.416445e-01 | 0.193 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 6.422178e-01 | 0.192 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 6.439083e-01 | 0.191 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 6.439083e-01 | 0.191 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 6.439083e-01 | 0.191 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 6.439083e-01 | 0.191 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 6.439083e-01 | 0.191 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 6.446815e-01 | 0.191 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 6.479067e-01 | 0.188 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.491011e-01 | 0.188 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 6.513201e-01 | 0.186 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 6.513201e-01 | 0.186 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.513201e-01 | 0.186 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 6.537050e-01 | 0.185 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 6.577845e-01 | 0.182 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 6.577845e-01 | 0.182 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 6.577845e-01 | 0.182 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 6.577845e-01 | 0.182 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 6.577845e-01 | 0.182 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 6.577845e-01 | 0.182 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 6.577845e-01 | 0.182 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 6.577845e-01 | 0.182 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 6.577845e-01 | 0.182 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 6.607868e-01 | 0.180 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.634209e-01 | 0.178 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.692187e-01 | 0.174 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 6.700460e-01 | 0.174 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 6.700460e-01 | 0.174 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.711207e-01 | 0.173 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 6.711207e-01 | 0.173 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 6.711207e-01 | 0.173 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 6.711207e-01 | 0.173 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 6.711207e-01 | 0.173 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 6.711207e-01 | 0.173 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 6.711207e-01 | 0.173 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 6.711207e-01 | 0.173 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 6.711207e-01 | 0.173 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 6.711207e-01 | 0.173 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 6.711207e-01 | 0.173 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 6.711207e-01 | 0.173 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 6.711207e-01 | 0.173 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 6.711207e-01 | 0.173 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 6.718528e-01 | 0.173 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 6.778648e-01 | 0.169 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 6.784330e-01 | 0.168 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 6.784330e-01 | 0.168 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 6.818019e-01 | 0.166 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 6.839380e-01 | 0.165 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 6.839380e-01 | 0.165 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 6.839380e-01 | 0.165 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 6.839380e-01 | 0.165 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 6.839380e-01 | 0.165 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 6.839380e-01 | 0.165 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 6.875326e-01 | 0.163 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 6.962565e-01 | 0.157 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 6.962565e-01 | 0.157 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 6.962565e-01 | 0.157 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 6.962565e-01 | 0.157 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 6.962565e-01 | 0.157 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 6.962565e-01 | 0.157 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 6.965980e-01 | 0.157 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 7.000119e-01 | 0.155 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 7.037302e-01 | 0.153 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 7.050471e-01 | 0.152 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 7.050471e-01 | 0.152 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 7.050471e-01 | 0.152 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 7.063096e-01 | 0.151 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 7.080956e-01 | 0.150 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 7.080956e-01 | 0.150 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 7.080956e-01 | 0.150 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 7.080956e-01 | 0.150 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 7.080956e-01 | 0.150 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 7.080956e-01 | 0.150 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 7.080956e-01 | 0.150 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 7.132993e-01 | 0.147 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 7.194740e-01 | 0.143 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 7.194740e-01 | 0.143 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 7.194740e-01 | 0.143 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 7.194740e-01 | 0.143 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 7.194740e-01 | 0.143 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 7.213571e-01 | 0.142 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 7.213571e-01 | 0.142 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 7.247222e-01 | 0.140 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 7.285467e-01 | 0.138 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 7.292231e-01 | 0.137 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 7.292231e-01 | 0.137 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 7.304095e-01 | 0.136 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 7.304095e-01 | 0.136 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 7.304095e-01 | 0.136 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 7.304095e-01 | 0.136 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 7.304095e-01 | 0.136 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 7.304095e-01 | 0.136 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 7.304095e-01 | 0.136 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 7.304095e-01 | 0.136 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 7.304095e-01 | 0.136 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 7.304095e-01 | 0.136 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 7.304095e-01 | 0.136 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 7.304095e-01 | 0.136 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 7.304095e-01 | 0.136 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 7.304095e-01 | 0.136 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 7.304095e-01 | 0.136 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.322147e-01 | 0.135 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 7.335001e-01 | 0.135 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 7.369000e-01 | 0.133 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 7.369000e-01 | 0.133 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 7.400033e-01 | 0.131 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 7.409194e-01 | 0.130 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 7.409194e-01 | 0.130 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 7.409194e-01 | 0.130 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 7.409194e-01 | 0.130 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 7.409194e-01 | 0.130 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 7.409194e-01 | 0.130 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 7.409194e-01 | 0.130 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.409194e-01 | 0.130 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 7.510201e-01 | 0.124 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 7.510201e-01 | 0.124 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 7.510201e-01 | 0.124 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 7.510201e-01 | 0.124 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.510201e-01 | 0.124 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 7.516978e-01 | 0.124 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 7.516978e-01 | 0.124 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 7.516978e-01 | 0.124 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 7.516978e-01 | 0.124 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 7.516978e-01 | 0.124 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 7.516978e-01 | 0.124 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 7.516978e-01 | 0.124 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 7.516978e-01 | 0.124 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 7.521375e-01 | 0.124 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 7.545652e-01 | 0.122 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 7.581129e-01 | 0.120 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.586830e-01 | 0.120 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 7.603524e-01 | 0.119 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 7.607277e-01 | 0.119 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 7.607277e-01 | 0.119 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 7.607277e-01 | 0.119 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.607277e-01 | 0.119 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 7.607277e-01 | 0.119 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.607277e-01 | 0.119 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 7.607277e-01 | 0.119 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 7.628818e-01 | 0.118 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 7.639714e-01 | 0.117 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 7.644910e-01 | 0.117 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 7.657734e-01 | 0.116 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 7.657734e-01 | 0.116 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 7.657734e-01 | 0.116 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.697143e-01 | 0.114 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 7.700573e-01 | 0.113 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 7.700573e-01 | 0.113 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.729971e-01 | 0.112 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 7.791508e-01 | 0.108 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 7.862608e-01 | 0.104 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 7.876410e-01 | 0.104 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 7.876410e-01 | 0.104 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 7.931525e-01 | 0.101 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 7.958274e-01 | 0.099 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 7.959227e-01 | 0.099 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 7.959227e-01 | 0.099 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 7.959227e-01 | 0.099 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 7.959227e-01 | 0.099 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 7.967361e-01 | 0.099 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 8.038820e-01 | 0.095 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.038820e-01 | 0.095 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 8.038820e-01 | 0.095 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 8.038820e-01 | 0.095 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 8.038820e-01 | 0.095 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 8.038820e-01 | 0.095 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 8.039086e-01 | 0.095 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 8.056167e-01 | 0.094 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 8.067792e-01 | 0.093 | 0 | 0 |
| Immune System | R-HSA-168256 | 8.072561e-01 | 0.093 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 8.097002e-01 | 0.092 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 8.115313e-01 | 0.091 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 8.115313e-01 | 0.091 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 8.115313e-01 | 0.091 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 8.133374e-01 | 0.090 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 8.188827e-01 | 0.087 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 8.188827e-01 | 0.087 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 8.188827e-01 | 0.087 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 8.208277e-01 | 0.086 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.259478e-01 | 0.083 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 8.259478e-01 | 0.083 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.259478e-01 | 0.083 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 8.259478e-01 | 0.083 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 8.270513e-01 | 0.082 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 8.300700e-01 | 0.081 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.327377e-01 | 0.079 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 8.327377e-01 | 0.079 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 8.345422e-01 | 0.079 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 8.364262e-01 | 0.078 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.383513e-01 | 0.077 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 8.383513e-01 | 0.077 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 8.386901e-01 | 0.076 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 8.392631e-01 | 0.076 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 8.392631e-01 | 0.076 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 8.392631e-01 | 0.076 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 8.392631e-01 | 0.076 | 0 | 0 |
| Disease | R-HSA-1643685 | 8.439298e-01 | 0.074 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 8.455343e-01 | 0.073 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 8.455343e-01 | 0.073 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 8.455343e-01 | 0.073 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 8.455343e-01 | 0.073 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 8.455343e-01 | 0.073 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 8.455343e-01 | 0.073 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.455343e-01 | 0.073 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 8.455343e-01 | 0.073 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.507869e-01 | 0.070 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 8.509117e-01 | 0.070 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 8.515612e-01 | 0.070 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 8.515612e-01 | 0.070 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 8.515612e-01 | 0.070 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 8.515612e-01 | 0.070 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.548026e-01 | 0.068 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 8.553128e-01 | 0.068 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 8.553128e-01 | 0.068 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 8.553128e-01 | 0.068 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 8.573533e-01 | 0.067 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 8.573533e-01 | 0.067 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.574322e-01 | 0.067 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 8.596913e-01 | 0.066 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 8.615153e-01 | 0.065 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 8.629198e-01 | 0.064 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 8.643656e-01 | 0.063 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 8.660338e-01 | 0.062 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 8.681484e-01 | 0.061 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 8.682693e-01 | 0.061 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 8.694919e-01 | 0.061 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 8.694919e-01 | 0.061 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.725444e-01 | 0.059 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 8.734104e-01 | 0.059 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 8.734104e-01 | 0.059 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 8.734104e-01 | 0.059 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 8.734104e-01 | 0.059 | 0 | 0 |
| Methylation | R-HSA-156581 | 8.734104e-01 | 0.059 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 8.734104e-01 | 0.059 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.739764e-01 | 0.059 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 8.757713e-01 | 0.058 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.776878e-01 | 0.057 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 8.783512e-01 | 0.056 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.830994e-01 | 0.054 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.830994e-01 | 0.054 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 8.830994e-01 | 0.054 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.843699e-01 | 0.053 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 8.876626e-01 | 0.052 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 8.876626e-01 | 0.052 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 8.897906e-01 | 0.051 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 8.920628e-01 | 0.050 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 8.962623e-01 | 0.048 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 8.962623e-01 | 0.048 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.003124e-01 | 0.046 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.033303e-01 | 0.044 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 9.042046e-01 | 0.044 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.042046e-01 | 0.044 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.042046e-01 | 0.044 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.042046e-01 | 0.044 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.042046e-01 | 0.044 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 9.098388e-01 | 0.041 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.115397e-01 | 0.040 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.125280e-01 | 0.040 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.125280e-01 | 0.040 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.160875e-01 | 0.038 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.164423e-01 | 0.038 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.179635e-01 | 0.037 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.183140e-01 | 0.037 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.185456e-01 | 0.037 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 9.215043e-01 | 0.036 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.215043e-01 | 0.036 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.215043e-01 | 0.036 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 9.215043e-01 | 0.036 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.245702e-01 | 0.034 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.255247e-01 | 0.034 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.303480e-01 | 0.031 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.303480e-01 | 0.031 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.303480e-01 | 0.031 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.303480e-01 | 0.031 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 9.303480e-01 | 0.031 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.330690e-01 | 0.030 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.330690e-01 | 0.030 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.356838e-01 | 0.029 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.365238e-01 | 0.028 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.387180e-01 | 0.027 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.394987e-01 | 0.027 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.401146e-01 | 0.027 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 9.406115e-01 | 0.027 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 9.406115e-01 | 0.027 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.406115e-01 | 0.027 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.406891e-01 | 0.027 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.419629e-01 | 0.026 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.429321e-01 | 0.026 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 9.429321e-01 | 0.026 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.455960e-01 | 0.024 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 9.462474e-01 | 0.024 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.477241e-01 | 0.023 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.483317e-01 | 0.023 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.483317e-01 | 0.023 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.483317e-01 | 0.023 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.490508e-01 | 0.023 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.493647e-01 | 0.023 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.493647e-01 | 0.023 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 9.544250e-01 | 0.020 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 9.544250e-01 | 0.020 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.550732e-01 | 0.020 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.568294e-01 | 0.019 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.568294e-01 | 0.019 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.568294e-01 | 0.019 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.585172e-01 | 0.018 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 9.601390e-01 | 0.018 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.601390e-01 | 0.018 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.626475e-01 | 0.017 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.631952e-01 | 0.016 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.631952e-01 | 0.016 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.651626e-01 | 0.015 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.666811e-01 | 0.015 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.686236e-01 | 0.014 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 9.710301e-01 | 0.013 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 9.724155e-01 | 0.012 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.733327e-01 | 0.012 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.751094e-01 | 0.011 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 9.762706e-01 | 0.010 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.771992e-01 | 0.010 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.797866e-01 | 0.009 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.797866e-01 | 0.009 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.808421e-01 | 0.008 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.818930e-01 | 0.008 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.819905e-01 | 0.008 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.819905e-01 | 0.008 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.840822e-01 | 0.007 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.850788e-01 | 0.007 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.853043e-01 | 0.006 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.858798e-01 | 0.006 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.858798e-01 | 0.006 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.869641e-01 | 0.006 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 9.869641e-01 | 0.006 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 9.869641e-01 | 0.006 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 9.869641e-01 | 0.006 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 9.874747e-01 | 0.005 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.874747e-01 | 0.005 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.881398e-01 | 0.005 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.897519e-01 | 0.004 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 9.898058e-01 | 0.004 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.901450e-01 | 0.004 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.906720e-01 | 0.004 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.911327e-01 | 0.004 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.914372e-01 | 0.004 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 9.916013e-01 | 0.004 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.919305e-01 | 0.004 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 9.919305e-01 | 0.004 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.920157e-01 | 0.003 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.922467e-01 | 0.003 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.922890e-01 | 0.003 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.925560e-01 | 0.003 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.928427e-01 | 0.003 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 9.931232e-01 | 0.003 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.936519e-01 | 0.003 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 9.939008e-01 | 0.003 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.945906e-01 | 0.002 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 9.950065e-01 | 0.002 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 9.950065e-01 | 0.002 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 9.955714e-01 | 0.002 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 9.955714e-01 | 0.002 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.958360e-01 | 0.002 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.960184e-01 | 0.002 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.960725e-01 | 0.002 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.962098e-01 | 0.002 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.967850e-01 | 0.001 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.970968e-01 | 0.001 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.971489e-01 | 0.001 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.972386e-01 | 0.001 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.984983e-01 | 0.001 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.986140e-01 | 0.001 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.987929e-01 | 0.001 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.991858e-01 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 9.996379e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.997218e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.997900e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.998478e-01 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 9.998596e-01 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.999822e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999848e-01 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.999934e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999948e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999985e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999998e-01 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.999999e-01 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.999999e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |